0
New drug baxdrostat shows long-term efficacy in resistant hypertension
□ 0 live♙ 0 following
New Phase III data presented at ESC 2026 show baxdrostat reduces systolic blood pressure by 12.6 mmHg over 52 weeks in patients with uncontrolled or resistant hypertension.